Back
IVL-DrugFluidic®
Technology Introduction
DrugFluidic® is a long-acting injectable platform based on microfluidic technology. It precisely controls the size, uniformity, and release rate of microparticles to achieve stable and predictable drug release. Depending on the potency and dosage of the drug, dosing intervals can be flexibly designed from 1 to 6 months. By scaling up the established formulation conditions through multi-channel parallelization, we ensure consistent quality and high scale-up reproducibility from research to commercial production. This platform is applicable to various active ingredients, including small molecules and peptides, contributing to improved patient convenience and treatment compliance in chronic disease management.
Business Model
1. In-house Pipeline License-out
Inventage Lab develops in-house long-acting injectable pipelines based on the DrugFluidic® platform. We promote commercialization through license-out to global and domestic pharmaceutical companies with clinical and commercial capabilities. We conduct internal development from initial formulation design to the level where entry into non-clinical and clinical stages is possible, then accelerate development, licensing, and commercialization through collaboration with partners to maximize the platform value and commercial potential.
2. Feasibility Study based Research Collaboration
Inventage Lab conducts collaborative research based on Feasibility Studies to verify the applicability of the DrugFluidic® platform to partners' candidates. We adopt a phased collaboration structure that expands to co-development or license-out after proving the feasibility of long-acting formulation and technical differentiation through short-term formulation evaluation. This allows partners to review new formulation options while minimizing development risk, while Inventage Lab continuously secures platform scalability and business opportunities.
